Descending duodenal adenocarcinoma treated with pembrolizumab resulting in complete clinical response: A case report and literature review

Figure 3 After receiving pembrolizumab. A: After receiving 2 cycles of pembrolizumab. computed tomography (CT) showed that the duodenal mass was significantly smaller than before; B and C: After receiving pembrolizumab for 2 years. Positron emission tomography/CT showed low density at the lateral pancreatic head attached to the duodenum and no increase in metabolism; D and E: After receiving 4 years of pembrolizumab. CT revealed no thickening of the duodenal wall (D). Upper gastrointestinal endoscopy showed smooth mucosa in the descending duodenum (E).